Novartis AG (SWX:NOVN)
105.50
-0.48 (-0.45%)
At close: Dec 12, 2025
Novartis AG Employees
Novartis AG had 75,883 employees as of December 31, 2024. The number of employees decreased by 174 or -0.23% compared to the previous year.
Employees
75,883
Change (1Y)
-174
Growth (1Y)
-0.23%
Revenue / Employee
592.36K CHF
Profits / Employee
151.24K CHF
Market Cap
202.43B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 75,883 | -174 | -0.23% |
| Dec 31, 2023 | 76,057 | -25,646 | -25.22% |
| Dec 31, 2022 | 101,703 | -2,620 | -2.51% |
| Dec 31, 2021 | 104,323 | -1,471 | -1.39% |
| Dec 31, 2020 | 105,794 | 1,880 | 1.81% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Roche Holding AG | 103,249 |
| Alcon | 25,599 |
| Sandoz Group AG | 22,049 |
| Lonza Group AG | 18,944 |
| Sonova Holding AG | 18,366 |
| Straumann Holding AG | 11,815 |
| Galenica AG | 7,971 |
| Galderma Group AG | 6,545 |
Novartis AG News
- 1 day ago - Novartis (NVS) Expands Manufacturing Presence in North Carolina - GuruFocus
- 1 day ago - Novartis Breaks Ground In North Carolina For New Manufacturing Hub, To Create 700 New Jobs - Nasdaq
- 1 day ago - Novartis breaks ground on flagship manufacturing hub in North Carolina - GlobeNewsWire
- 4 days ago - Novartis' Investigational Drug Reports Longer Disease Control In Patients With Rare Blood Disorder - Benzinga
- 4 days ago - Novartis' Investigational Drug Reports Longer Disease Control In Patients With Rare Blood Disorder - Benzinga
- 4 days ago - Novartis sees positive results when ianalumab added to Promacta for thrombocytopenia - Seeking Alpha
- 4 days ago - Novartis (NVS) Reveals Promising Kisqali Results for Advanced Breast Cancer - GuruFocus
- 4 days ago - Novartis (NVS) Reports Positive Phase III Trial Results for Ianalumab in ITP - GuruFocus